To access the appropriate site, please select from the following options:

If you are a patient/carer/member of the public or healthcare professional looking for information on CRYSVITA, please click the corresponding link.

Otherwise, if you would like information on X-linked hypophosphataemia, please click on the last link.

Information on X-linked hypophosphataemia
Please note all three websites accessed via these links are developed and funded by Kyowa Kirin International.
You are about to leave a Kyowa Kirin website.

The site you are about to go to is not under the control of Kyowa Kirin International. Kyowa Kirin International is not responsible for the content of any such site or any further link from such site.

Are you sure you want to continue?

Yes
Crysvita.eu
Paediatric Dosing Factsheet Adult Dosing Factsheet UK Prescribing Information Prescribing Information Patient Site
  • What is XLH?
    • Causes of XLH
    • Clinical manifestations
    • Prevalence
    • Hereditary pattern
  • How does CRYSVITA work?
    • FGF23 and XLH
    • CRYSVITA mode of action
    • Phosphate homeostasis
  • Why CRYSVITA?
    • Paediatric Studies
    • Adult Studies
  • Starting CRYSVITA
    • Dosing
    • Administration
    • Monitoring
    • Storage
  • Resources
    • Downloadable materials
    • Webinars
    • Publications of interest
    • Key facts
    • Useful websites
Prescribing Information

UK Prescribing Information

▼ CRYSVITA® (Burosumab)

Please refer to Summary of Product Characteristics (SmPC) before prescribing.

Presentation: Each vial contains 10/20/30 mg burosumab in 1 mL solution for injection. Contains 45.91 mg/mL sorbitol. Indication: Treatment of X-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. Dosage and Administration: At initiation, fasting serum phosphate concentration should be below the reference range for age. For subcutaneous use. Treatment should be initiated by a Physician experienced in the management of patients with metabolic bone diseases. Discontinue oral phosphate and active vitamin D analogues 1 week prior to initiation of treatment. Recommended starting dose in children and adolescents aged 1 to 17 years is 0.8 mg/kg of bodyweight every 2 weeks. Maximum dose 90 mg. Round dose to the nearest 10 mg. Dose conversion at age 18 years: At 18 years of age, the patient should convert to the adult dose and dosing regimen. Recommended starting dose in adults is 1.0 mg/kg of bodyweight every 4 weeks. Maximum dose 90 mg. Round dose to the nearest 10 mg. Inject in arm, abdomen, buttock or thigh, 1.5 ml max. volume per site. If >1.5 mL is required, split total volume over two sites. Rotate sites and monitor for signs of reactions. Dose Adjustments: Measure fasting serum phosphate and adjust dose accordingly (not more frequently than every 4 weeks) (see SmPC). Special Populations: Safety/efficacy not established in renal impairment and age <1 year. Limited data are available in patients over 65 years of age. Contraindications: Hypersensitivity to ingredients (Refer to SmPC). Concurrent administration with oral phosphate, active vitamin D analogues. Fasting serum phosphate above normal range for age. Severe renal impairment or end stage renal disease. Warnings and Precautions: Ectopic mineralisation: stop oral phosphate and active vitamin D analogues at least 1 week prior to treatment. Monitor for signs and symptoms of nephrocalcinosis at the start of treatment and every 6 months for the first year and annually thereafter. Monitor plasma alkaline phosphatases (ALP), calcium, parathyroid hormone (PTH) and creatinine every 6 months (3 months for children 1- 2 years). Monitor urine calcium and phosphate every 3 months. Hyperphosphataemia: monitor fasting serum phosphate. Dose interruption and/or reduction may be required. Measure post-prandial serum phosphate and PTH periodically. Injection site reactions: Administration should be interrupted in any patient experiencing severe injection site reactions. Hypersensitivity: discontinue CRYSVITA® if serious reactions occur. Drug Interactions: Concurrent oral phosphate and active vitamin D analogues contraindicated (increased risk of hyperphosphataemia and hypercalcaemia). Caution when combining with calcimimetic medicinal products (potential to exacerbate hypocalcaemia). Pregnancy and Lactation: CRYSVITA is not recommended during pregnancy and in women of childbearing potential not using contraception. There are no or limited amount of data in pregnant women. Studies in animals have shown reproductive toxicity. It is unknown whether burosumab/ metabolites are excreted in human milk. A risk to newborns/infants cannot be excluded. Undesirable effects (Refer to SmPC for full summary of safety profile): Mild or moderate hypersensitivity reactions (including: injection site rash, rash, urticaria, swelling face, dermatitis) were reported in 18% of paediatric patients and 6% of adult patients. The most common adverse drug effects in paediatric patients were: injection site reactions (56%), cough (56%), headache (50%), pyrexia (43%), pain in extremity (40%), vomiting (39%), tooth abscess (35%), vitamin D decrease (32%), diarrhoea (25%), rash (24%), nausea (15%), constipation (11%), dental caries (11%) and myalgia (11%). The most common adverse drug reactions in adult patients were: back pain (23%), headache (21%), tooth infection (19%), vitamin D decrease (15%), restless legs syndrome (13%), muscle spasms (12%), and dizziness (11%). Date of Preparation of Prescribing Information: September 2020. Legal Category: POM. Marketing Authorisation numbers and list price: 1 x CRYSVITA 10mg; EU/1/17/1262/001, £2,992. 1 x CRYSVITA 20 mg; EU/1/17/1262/002, £5,984. 1 x CRYSVITA 30 mg; EU/1/17/1262/003, £8,976. Marketing Authorisation holder: Kyowa Kirin Holdings B.V., Bloemlaan 2, 2132NP Hoofddorp, The Netherlands, +31 (0) 237200822.

CRYSVITA has a conditional Marketing Authorisation in Europe. A conditional authorisation in Europe is granted when a medical product meets an important medical need and when the availability and benefit to health outweighs the risk in additional data being required. The European regulatory agency will review new information on CRYSVITA annually and the Summary of Product Characteristics will be updated accordingly.

Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Kyowa Kirin Ltd on +44 (0)1896 664000, email This email address is being protected from spambots. You need JavaScript enabled to view it.

® Registered trademark                                                                     KKI/UK/CYS/0029

Kyowa Kirin Logo

Website developed and funded by Kyowa Kirin International. © 2019 Kyowa Kirin International Plc. All rights reserved.
CRYSVITA® is a registered trademark of Kyowa Kirin Co., Ltd.
September 2021 KKI/INT/BUR/1053

  • Abbreviations
  • Contact Us
  • Cookies
  • Privacy Notice
  • Terms of Use

This website uses analytic cookies for content measurement and to remember your preferences. By clicking Accept you agree to the use of cookies on this site. For more details about how we use cookies visit the Cookies page.